Description

MicroarrayPanel:Commoncancers(2)No.ofsamples59No.ofpatients59Corediameter2.0mmFormat:FormalinFixedSectionthickness4micrometer Core#No. Age Sex Organ Diagnosis pTNM Stage MBN4# Tissuetype Image 1 66 F Breast infiltratingductcarcinoma T2N0M0 IIA . 6 "class="fd_image"> 2 43 F Breast infiltratingductcarcinoma T3N2aM0 IIIA 102 6 "class="fd_image"> 3 58 F Breast infiltratingductcarcinoma T2N3aM0 IIIC 103 6 "class="fd_image"> 4 46 F Breast infiltratingductcarcinoma T3N1aM0 IIIA 104 6 "class="fd_image"> 5 71 F Breast infiltratingpapillarycarcinomawithsignetringcellcarcinoma T3N1aM0 IIIA 105 6 "class="fd_image"> 6 37 F Breast infiltratingductcarcinoma T3N3aM0 IIIC 106 6 "class="fd_image"> 7 53 F Breast mixedinfiltratingductandlobularcarcinoma T3N2aM0 IIIA . 6 "class="fd_image"> 8 30 F Breast medullarycarcinoma T3N0M0 IIB 108 6 "class="fd_image"> 9 47 F Breast atypicalmedullarycarcinoma T2N1aM0 IIB 109 6 "class="fd_image"> 10 44 F Breast infiltratingductalcarcinoma T2N0M0 IIA . 6 "class="fd_image"> 11 32 M Liver combinedhepatocellularandcholangiocarcinoma T3N0M0 IIA 111 6 "class="fd_image"> 12 57 M Liver hepatocellularcarcinoma T3N0M0 IIIA 112 6 "class="fd_image"> 13 58 F Liver hepatocellularcarcinoma T3N0M0 IIIA . 6 "class="fd_image"> 14 20 M Liver hepatocellularcarcinoma T4N0M0 IIIB . 6 "class="fd_image"> 15 63 F Liver hepatocellularcarcinoma T1N0M0 I . 6 "class="fd_image"> 16 66 F Liver hepatocellularcarcinoma T1N0M0 I . 6 "class="fd_image"> 17 61 M Liver hepatocellularcarcinoma T1N0M0 I 117 6 "class="fd_image"> 18 52 M Liver hepatocellularcarcinoma T3N0M0 IIIA . 6 "class="fd_image"> 19 50 M Liver combinedhepatocellularandcholangiocarcinoma T3N1M0 IIIC 119 6 "class="fd_image"> 20 56 M Liver hepatocellularcarcinoma T3N0M0 IIIA . 6 "class="fd_image"> 21 53 M Urinarybladder mucinousadenocarcinomafromurachalremnant T4bN0M0 IV 121 6 "class="fd_image"> 22 60 M Urinarybladder transitionalcellcarcinoma T3bN1M0 IV . 6 "class="fd_image"> 23 60 M Urinarybladder transitionalcellcarcinoma T3bN1M0 IV 123 6 "class="fd_image"> 24 65 M Urinarybladder transitionalcellcarcinoma T4aN1M1 IV 124 6 "class="fd_image"> 25 74 M Urinarybladder transitionalcellcarcinoma T1N0M0 I 125 6 "class="fd_image"> 26 63 F Urinarybladder transitionalcellcarcinoma T1N0M0 I 126 6 "class="fd_image"> 27 58 M Urinarybladder transitionalcellcarcinoma T3NXM0 III . 6 "class="fd_image"> 28 46 M Urinarybladder transitionalcellcarcinoma T1N0M0 I 128 6 "class="fd_image"> 29 76 M Urinarybladder transitionalcellcarcinoma T3NXM0 III . 6 "class="fd_image"> 30 63 M Urinarybladder transitionalcellcarcinoma T3bN0M0 III 130 6 "class="fd_image"> 31 57 F Ovary SEROusadenocarcinoma T3bN1M0 IIIC . 6 "class="fd_image"> 32 48 F Ovary serousadenocarcinoma,moderatelydifferentiated T3cN0M0 IIIC . 6 "class="fd_image"> 33 60 F Ovary seroussurfacepapillarycarcinoma,poorlydifferentiated T2cN0M0 IIC 133 6 "class="fd_image"> 34 41 F Ovary serousadenocarcinoma,moderatelydifferentiated T2cN1M0 IIIC . 6 "class="fd_image"> 35 64 F Ovary serousadenocarcinoma T3cN0M0 IIIC 135 6 "class="fd_image"> 36 60 F Ovary serousadenocarcinoma T3cN1M0 IIIC . 6 "class="fd_image"> 37 54 F Ovary serousadenocarcinoma T3aN0M0 IIIA . 6 "class="fd_image"> 38 58 F Ovary serousadenocarcinoma T2cN0M0 IIC . 6 "class="fd_image"> 39 16 F Ovary mucinousadenocarcinoma T1aN0M0 IA . 6 "class="fd_image"> 40 57 F Ovary serousadenocarcinoma,poorlydifferentiated T3cN0M0 IIIC . 6 "class="fd_image"> 41 66 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T4N1M0 III 141 6 "class="fd_image"> 42 71 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB . 6 "class="fd_image"> 43 68 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB 143 6 "class="fd_image"> 44 45 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB 144 6 "class="fd_image"> 45 64 F Pancreas ductaladenocarcinoma,moderatelydifferentiated T4N0M0 III . 6 "class="fd_image"> 46 64 F Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB . 6 "class="fd_image"> 47 69 M Pancreas ductaladenocarcinoma,poorlydifferentiated T4NxM0 III 147 6 "class="fd_image"> 48 46 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB . 6 "class="fd_image"> 49 54 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB . 6 "class="fd_image"> 50 40 M Pancreas ductaladenocarcinoma,moderatelydifferentiated T3N1M0 IIB 150 6 "class="fd_image"> 51 85 M Prostate adenocarcinoma TxN0M1 IV . 6 "class="fd_image"> 52 79 M Prostate adenocarcinoma T2aN0M1 IV . 6 "class="fd_image"> 53 53 M Prostate adenocarcinoma T2aN0M1 IV . 6 "class="fd_image"> 54 68 M Prostate adenocarcinoma T2bN0M0 II . 6 "class="fd_image"> 55 82 M Prostate adenocarcinoma T2N0M1 IV . 6 "class="fd_image"> 56 76 M Prostate adenocarcinoma T3aN0M0 III . 6 "class="fd_image"> 57 56 M Prostate adenocarcinoma T2cN1M0 IV . 6 "class="fd_image"> 58 66 M Prostate adenocarcinoma T4N0M0 IV . 6 "class="fd_image"> 59 54 M Prostate adenocarcinoma T1aN0M0 II 159 6 "class="fd_image"> 60 . . Carbon . . . . . "class="fd_image">

Publications

ReadPublicationsusingNBP2-30263inthefollowingapplications: IHC-P 2publications

Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 【详细说明】  Novus Biologicals北京代理，Novus Biologicals中国代理，Novus Biologicals上海代理，Novus Biologicals公司，Novus Biologicals 上海普迈生物科技有限公司签约代理      欢迎下载下面的资料以了解此产品的相关信息！预询产品订购信息  上海普迈生物致力于提供zui高质量的产品和服务组织形态学研究与竞争力的产品 产品和服务,有相关产品的问题请直接 期货每周下午5点前发定单，正常到上海时间为3-4周 现市区2天内送到，外地以快递为准 敬请关注！ ：   :www.pumaibio.com :pumaibio :（直接客户） （经销商） 促销etonbio、polysciences、Mattek、trevigen、Chromogenix、cyguns、IrvineScientific、Innovative Cell Technologies、enzo、novus、immunochemistry、eylabs、Polyplus、NIBSC、ALZET、hitobiotec、sutter instrument、mirus、StressMarq、Avanti、jena bioscience、Neuro Probe、tedpella、avanti、Rockland、CAYMAN、transgenomic、BioLegend、ambion、omicronbio、 Assaybiotech、chondrex、lc?laboratories、cosmobio、megazyme、NeoMarkers、BTI、eylabs、berryassoc、cellagentech、TOCRIS、Relia Tech、SouthernBiotech、Biosearch technology、Lumiprobe、StemCells?Inc、biovendor、NORGEN、alomone、jena?bioscience、Gracebio、Eurogentec、Gelcompany?、invitrogen、gene?bridges、MRC-Holland、laysanbio